Efficacy of epidural Dexmedetomidine as analgesic adjunct to local anesthetic in patients undergoing major abdominal cancer surgery

In major abdominal cancer surgery, does epidural dexmedetomidine added to bupivacaine, compared to epidural bupivacaine only, reduce postoperative opioid consumption?

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12615000288527

Enrollment

Registered

2015-03-27

Start date

2015-01-25

Completion date

2016-01-20

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

evaluation of analgesic efficacy of epiduraly administered dexmedetomidine when given as analgesic adjunct to bupivacaine 0.125% in postoperative period after major abdominal cancer surgery.

Interventions

Before induction of anesthesia (pre-incision), for group BD, we will give epidural bolous dose of Dexmedetomidine 0.2 mic /kg added to 0.1 ml /kg of Bupivacaine 0.125%, then, we will give epidural infusion of Dexmedetomidine 0.2 mic /kg /h added to 0.1 ml /kg/h of Bupivacaine 0.125% for 48 h postoperatively . for group B, we will give epidural bolous dose of 0.1 ml /kg Bupivacaine 0.125%, then, we will give epidural infusion of 0.1 ml /kg/h of Bupivacaine 0.125% for 48 h postoperatively.

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

patients with physical status American Society of Anaesthesiologist (ASA) I , II and III who will undergo major abdominal cancer surgery will be enrolled into the study.

Exclusion criteria

Patients with coagulation abnormalities, spinal deformities, and patients allergic to amide type of local anesthetics or Dexmedetomidine will be excluded from the study.

Outcome results